Patritumab Deruxtecan is a medication being studied for its safety and effectiveness in treating gastrointestinal cancers. It is designed to target and deliver cancer-fighting agents directly to cancer cells, potentially reducing the growth of tumors. This medication is part of a clinical trial to understand how well it works and how safe it is for patients with these types of cancers.

Colorectal Carcinoma – This is a type of cancer that begins in the colon or rectum, parts of the large intestine. It often starts as small, benign clumps of cells called polyps, which can develop into cancer over time. As the disease progresses, it can invade deeper layers of the colon or rectum and spread to nearby lymph nodes or other organs. Symptoms may include changes in bowel habits, blood in the stool, and abdominal discomfort.

Biliary Tract Carcinoma – This cancer affects the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. It can develop in any part of the bile duct system and is often categorized based on its location. The disease may cause symptoms such as jaundice, itching, and abdominal pain as it progresses. It can spread to nearby tissues and organs, complicating its course.

Hepatocellular Carcinoma – This is the most common type of primary liver cancer, originating in the liver cells called hepatocytes. It often occurs in the context of chronic liver disease, such as cirrhosis or hepatitis. As the cancer grows, it can disrupt liver function and may spread to other parts of the body. Symptoms might include weight loss, upper abdominal pain, and jaundice.